Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)

被引：0

作者：

Lee, Yeh Chen

Castellano, Tara

Myers, Tashanna K. N.

Barnes, Elizabeth H.

Chase, Dana Meredith

McCormick, Colleen

Diamante, Katrina

Shannon, Catherine M.

Huh, Warner King

Lea, Jayanthi Sivasothy

Walker, Joan L.

Small, William, Jr.

Miller, Katherine

Govindarajulu, Geetha

Monk, Bradley J.

Stockler, Martin R.

Moore, Kathleen N.

Mileshkin, Linda R.

Bae-Jump, Victoria Lin

机构：

[1] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[2] Louisiana State Univ, Dept Gynecol Oncol, New Orleans, LA USA

[3] Baystate Med Ctr, Springfield, MA USA

[4] Univ Calif Los Angeles, Dept Obstet & Gynecol, Div Gynecol Oncol, Los Angeles, CA 90024 USA

[5] Univ New Mexico Canc Ctr, Albuquerque, NM USA

[6] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia

[7] Mater Canc Care Ctr, South Brisbane, Australia

[8] Univ Alabama Birmingham, Birmingham, AL USA

[9] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[10] Univ Oklahoma Hlth Sci Ctr, Oklahoma City, OK USA

[11] Loyola Univ Med Ctr, Maywood, IL 60153 USA

[12] Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA

[13] Calvary Mater Newcastle, Newcastle, NSW, Australia

[14] Univ Arizona Coll Med, HonorHlth Res Inst, Div Gynecol Oncol, Phoenix, AZ USA

[15] Creighton Univ Sch Med, Phoenix, AZ USA

[16] Univ Sydney, Camperdown, NSW, Australia

[17] Oklahoma Univ Hlth, Stephenson Canc Ctr, Oklahoma City, OK USA

[18] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[19] Peter MacCallum Canc Ctr, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

[20] Univ Melbourne, Melbourne, Vic, Australia

[21] Univ North Carolina Chapel Hill, Chapel Hill, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1594

引用

页数：1

共 41 条

[21] Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
Petrylak, Daniel P.
de Wit, Ronald
Chi, Kim N.
Drakaki, Alexandra
Sternberg, Cora N.
Nishiyama, Hiroyuki
Castellano, Daniel
Hussain, Syed A.
Flechon, Aude
Bamias, Aristotelis
Yu, Evan Y.
van der Heijden, Michiel S.
Matsubara, Nobuaki
Alekseev, Boris
Necchi, Andrea
Geczi, Lajos
Ou, Yen-Chuan
Coskun, Hasan Senol
Su, Wen-Pin
Bedke, Jens
Gakis, Georgios
Percent, Ivor J.
Lee, Jae-Lyun
Tucci, Marcello
Semenov, Andrey
Laestadius, Fredrik
Peer, Avivit
Tortora, Giampaolo
Safina, Sufia
Garcia del Muro, Xavier
Rodriguez-Vida, Alejo
Cicin, Irfan
Harputluoglu, Hakan
Tagawa, Scott T.
Vaishampayan, Ulka
Aragon-Ching, Jeanny B.
Hamid, Oday
Liepa, Astra M.
Wijayawardana, Sameera
Russo, Francesca
Walgren, Richard A.
Zimmermann, Annamaria H.
Hozak, Rebecca R.
Bell-McGuinn, Katherine M.
Powles, Thomas
LANCET ONCOLOGY, 2020, 21 (01): : 105 - 120
[22] Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses
Brose, M.
Jarzab, B.
Elisei, R.
Giannetta, L.
Bastholt, L.
de la Fouchardiere, C.
Pacini, F.
Paschke, R.
Nutting, C.
Shong, Y. K.
Sherman, S.
Smit, J.
Chung, J.
Meinhardt, G.
Schlumberger, M.
Kappeler, C.
ANNALS OF ONCOLOGY, 2016, 27
[23] Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial
Fransson, Per
Lund, Jo-Asmund
Damber, Jan-Erik
Klepp, Olbjorn
Wiklund, Fredrik
Fossa, Sophie
Widmark, Anders
LANCET ONCOLOGY, 2009, 10 (04): : 370 - 380
[24] Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial
Zhang, Qingyuan
Li, Wei
Hu, Xichun
Sun, Tao
Cui, Shude
Wang, Shusen
Ouyang, Quchang
Yin, Yongmei
Geng, Cuizhi
Tong, Zhongsheng
Cheng, Ying
Ning, Zhiqiang
Jiang, Zefei
TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
[25] Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
Johnston, Stephen R. D.
Kilburn, Lucy S.
Ellis, Paul
Dodwell, David
Cameron, David
Hayward, Larry
Im, Young-Hyuck
Braybrooke, Jeremy P.
Brunt, A. Murray
Cheung, Kwok-Leung
Jyothirmayi, Rema
Robinson, Anne
Wardley, Andrew M.
Wheatley, Duncan
Howell, Anthony
Coombes, Gill
Sergenson, Nicole
Sin, Hui-Jung
Folkerd, Elizabeth
Dowsett, Mitch
Bliss, Judith M.
LANCET ONCOLOGY, 2013, 14 (10): : 989 - 998
[26] First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
Yang, James Chih-Hsin
Kang, Jin Hyoung
Mok, Tony
Ahn, Myung-Ju
Srimuninnimit, Vichien
Lin, Chia-Chi
Kim, Dong-Wan
Tsai, Chun-Ming
Barraclough, Helen
Altug, Sedat
Orlando, Mauro
Park, Keunchil
EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2219 - 2230
[27] Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Dieras, Veronique
Miles, David
Verma, Sunil
Pegram, Mark
Welslau, Manfred
Baselga, Jose
Krop, Ian E.
Blackwell, Kim
Hoersch, Silke
Xu, Jin
Green, Marjorie
Gianni, Luca
LANCET ONCOLOGY, 2017, 18 (06): : 732 - 742
[28] Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
Zhou, Qing
Chen, Ming
Jiang, Ou
Pan, Yi
Hu, Desheng
Lin, Qin
Wu, Gang
Cui, Jiuwei
Chang, Jianhua
Cheng, Yufeng
Huang, Cheng
Liu, Anwen
Yang, Nong
Gong, Youling
Zhu, Chuan
Ma, Zhiyong
Fang, Jian
Chen, Gongyan
Zhao, Jun
Shi, Anhui
Lin, Yingcheng
Li, Guanghui
Liu, Yunpeng
Wang, Dong
Wu, Rong
Xu, Xinhua
Shi, Jianhua
Liu, Zhihua
Cui, Na
Wang, Jingru
Wang, Qiang
Zhang, Ran
Yang, Jason
Wu, Yi-Long
LANCET ONCOLOGY, 2022, 23 (02): : 209 - 219
[29] Re: Robert J. Motzer, Paul Russo, Naomi Haas, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol 2021;79:334-8 PROTECTing Patients with Locally Advanced Kidney Cancer
Singla, Nirmish
Pierorazio, Phillip
Allaf, Mohamad
Ged, Yasser
EUROPEAN UROLOGY, 2021, 80 (01) : E33 - E34
[30] Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management
J. Joshua Smith
Oliver S. Chow
Marc J. Gollub
Garrett M. Nash
Larissa K. Temple
Martin R. Weiser
José G. Guillem
Philip B. Paty
Karin Avila
Julio Garcia-Aguilar
BMC Cancer, 15

← 1 2 3 4 5 →